NF-1 Study: Everolimus for treatment of disfiguring cutaneous lesions in Neurofibromatosis 1

Volunteers are needed for a research study.

Objective: Determine if orally administered Everolimus reduces the surface volume of dermal cutaneous and subcutaneous neurofibromas in subjects with NF-1.

Inclusion: Adult patients with NF-1 and disfiguring cutaneous lesions that can be photographed will be screened for participation. Risks and benefits will be discussed with you.

Treatment: Everolimus will be administered orally daily for 6 months.

Study Procedures: 3D photographs of targeted lesion, blood tests including study drug levels, and biopsies of targeted lesions (different than the photographed target lesion). The photographs, blood tests and biopsies are at Baseline, 3 months, and 6 months. There is a blood test for study drug level at 2 weeks and at any change is dose.

Time Commitment: The study is for 6 months. Study visits are at 2 weeks after starting, and then monthly for the 6 months.

Location: The study is being conducted at The University of Texas Health Science Center at Houston in the Texas Medical Center.

Cost: The only cost to the subject is transportation. We pay for parking as well as study drug and all tests associated with the study.

Contact: Patti Tate by phone: 713-500-5659 or email: patti.l.tate@uth.tmc.edu

Principal Investigators: Mary Kay Koenig, MD and John Slopis, MD

Registered on clinicaltrials.gov: NCT # 02332902

UTHealth™ | Medical School

The University of Texas Health Science Center at Houston

UTHealth The University of Texas Health Science Center at Houston

IRB NUMBER: HSC-MS-14-0758
IRB APPROVAL DATE: 04/22/2015